Institutional Biosafety Commitee (IBC)
The function of the Institutional Biosafety Committee (IBC) is to ensure that research using recombinant or synthetic DNA, infectious agents, or select agents/toxins is carried out in conformity with federal guidelines. Questions regarding the IBC may be directed to email@example.com.
Biosafety Checklist (Word) (recommended that BLS2 labs conduct a self-audit on a yearly basis)
May 15, 2020 Update from the NIH Office of Science Policy: The NIH Office of Science Policy has issued Frequently Asked Questions (FAQs) regarding interim biosafety guidance for research with SARS-CoV-2 and relevant Institutional Biosafety Committee (IBC) requirements under the NIH Guidelines. Appendix B of the NIH Guidelines provides the basis for the classification of biohazardous agents by Risk Group (RG). At the present time, SARS-CoV-2 best meets the definition of a RG3 agent and IBCs should consider the agent to be RG3 as a starting point in their risk assessments when reviewing research subject to the NIH Guidelines. The RG classification may change over time as additional information about the virus, such as potential treatments or the development of an effective vaccine, becomes available.
For additional interim biosafety guidance for research with SARS-CoV-2 and IBC requirements under the NIH Guidelines please visit: https://osp.od.nih.gov/biotechnology/interim-lab-biosafety-guidance-for-research-with-sars-cov-2/.
Contact for Questions
Research Compliance Officer III
207.581.2657, 311 Alumni Hall
Amanda Ashe, CRA
Director of Research Compliance
207.581.1480, 310 Alumni Hall